We believe that HPV infected individuals should take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was designed to help the immune system target the latent human papillomavirus. - Mike Evans, polyDNA
Rochester, NY (PRWEB) July 02, 2014
Women with many sex partners may be infected with many types of HPV, which increases the risk of cancer. The American Association for Cancer research says that “The risk for developing the tissue abnormalities, or lesions, that typically precede cervical cancer is much higher for women infected with multiple genotypes of the human papillomavirus (HPV).” (See News-Medical.net, from July 10, 2006) (2) Women can click here to learn more about HPV and cervical cancer.
polyDNA recommends that individuals infected with HPV take Novirin or Gene-Eden-VIR. The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy in September 2013, the first in a special edition on Advances in Antiviral Drugs. Study authors wrote that individuals infected with (certain viruses) reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR. (3) The study authors also wrote that, ‘We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.’ (3) In addition, this natural antiviral was recently proven to reduce mental and physical fatigue in a post-marketing clinical study that followed FDA guidelines.
Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.
“Although doctors have known that the cervical tissue at the opening to the womb can harbor multiple HPV types…the risk for developing cervical cancer, the second most common form of cancer in women worldwide, is higher in females infected with multiple HPV types than those infected with just one HPV type.” (2)
Dr. Eduardo L. Franco, Dr.PH. said that “Women who harbor multiple infections are at higher risk for cervical lesions than those ever infected with one type only and should be followed more closely.” (2) Dr. Franco is a professor of epidemiology and oncology, and director, division of cancer epidemiology at McGill University.
“We believe that HPV infected individuals should take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was designed to help the immune system target the latent human papillomavirus.” - Mike Evans, polyDNA
All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured. To contact a polyDNA representative, please call
(1) Smith MA1, Tellier PP, Roger M, Coutlée F, Franco EL, Richardson H. Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioral and biologic factors. Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):812-22.
(2) News-Medical.net - Women who harbor multiple HPV type infections are at higher risk for cervical lesions. P ublished July 10, 2006
(3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 http://dx.doi.org/10.4236/pp.2013.46A001